All relevant data are within the paper.

Introduction {#sec001}
============

Psoriasis is one of the most common chronic-inflammatory diseases of the skin and joints with high impact on emotional and social well-being, life course and occupational career \[[@pone.0129120.ref001]\]. The well-being of affected patients is not only influenced by the psoriasis itself, but also by its management \[[@pone.0129120.ref002],[@pone.0129120.ref003]\]. To identify an effective treatment with reasonable risks and costs, physicians often chose a stepwise approach starting with topical and phototherapy, escalating to traditional systemic medication and ending with biologicals \[[@pone.0129120.ref004]\].

Biologicals approved as second-line treatments for refractory psoriasis in Germany consist of the TNF antagonists etanercept, adalimumab and infliximab and the interleukin 12/23 antagonist ustekinumab. All of them have a favourable benefit-risk profile \[[@pone.0129120.ref004],[@pone.0129120.ref005]\] but they possess some differences in response rates, rapidity of action and sustainability \[[@pone.0129120.ref006]--[@pone.0129120.ref008]\]. Chances of achieving reduction of the Psoriasis Area and Severity Index (PASI) by 50, 75 or 90% (PASI 50, 75 or 90 response rates) are higher for infliximab, ustekinumab and adalimumab than for etanercept \[[@pone.0129120.ref006]\]. Onset of action is fastest for infliximab, followed by ustekinumab and adalimumab \[[@pone.0129120.ref008]\]. Both TNF antagonists and ustekinumab are approved for psoriatic arthritis, but American College of Rheumatology (ACR) 20 response rates may be somewhat higher for TNF antagonists \[[@pone.0129120.ref009],[@pone.0129120.ref010]\]. Moreover, the treatment process, i.e., the mode and frequency of application of each biological is different. Etanercept, adalimumab and ustekinumab are administered subcutaneously (etanercept and adalimumab with a pen or a prefilled syringe, ustekinumab with a prefilled syringe). Infliximab is given intravenously as infusion. Etanercept has to be applied once to twice weekly, adalimumab every two weeks, infliximab every eight and ustekinumab every 12 weeks.

Patients with psoriasis receiving biologicals are on average very satisfied with their treatment, whereas patients with other treatments report higher dissatisfaction, often caused by discordance between treatment requirements and individual needs \[[@pone.0129120.ref002]\]. This contributes to high rates of non-adherence \[[@pone.0129120.ref002],[@pone.0129120.ref011],[@pone.0129120.ref012]\]. One way to improve treatment satisfaction, adherence and thereby outcome is integration of patients' preferences into shared decision-making. Patients' preferences for psoriasis treatments were assessed in a number of studies and with different techniques, some of which originally stem from marketing research \[[@pone.0129120.ref013]--[@pone.0129120.ref017]\]. We previously performed conjoint analysis (CA), a method imitating the trade-off process typical of clinical decision-making, to elicit patients' preferences for psoriasis treatments \[[@pone.0129120.ref018]--[@pone.0129120.ref021]\]. We showed that when faced with all kinds of treatment options including topical therapy, phototherapy, traditional systemic therapy and biologicals patients prioritize an efficient and convenient outpatient therapy \[[@pone.0129120.ref018]\]. The aim of the present study was to identify patients' preferences for outcome and process attributes of biologicals and to study the impact of sociodemographic and socioeconomic factors and disease severity on these preferences.

Materials and Methods {#sec002}
=====================

Study participants {#sec003}
------------------

Preferences of patients with moderate-to-severe psoriasis for the attributes of biologicals were assessed in an open cross-sectional study at the Department of Dermatology of the University Medical Center Mannheim, Germany. All patients presenting to our outpatient department with moderate-to-severe psoriasis were pre-screened to determine their eligibility to participate in the study. Every eligible patient was asked to participate. Participants who had provided written informed consent were carefully examined and checked for inclusion and exclusion criteria. Inclusion criteria were age ≥18 years and moderate-to-severe psoriasis according to the criteria of the Committee for Medicinal Products for Human Use (CMPH), i.e., PASI≥10 in the course of the disease, involvement of head, palms or plantar surfaces, or psoriatic arthritis according to Classification of Psoriatic Arthritis (CASPAR) criteria with any skin involvement \[[@pone.0129120.ref022]\]. Diagnosis of psoriasis was based on clinical examination, combined with histology if the clinical diagnosis was questionable. Both patients with and without current antipsoriatic treatment were eligible for participation. Exclusion criteria were other diagnoses than moderate-to-severe psoriasis and inability to complete the survey due to difficulties with the German language or incapacity to understand CA exercises (i.e., failing to answer exercises with unambiguous scenarios presented for control). The study was performed according to the principles of the Declaration of Helsinki and approved by the Ethics Committee of the Medical Faculty Mannheim (Ethics Approval 2009-329E-MA, 22 October 2009; Amendment 27 September 2012).

Data collection {#sec004}
---------------

Participants were assigned an identification code to access a computerized survey before clinical consultation. The first part contained information on sociodemographic characteristics (age \[in years\], gender and partnership \[living with or without a partner\]) and socioeconomic characteristics (working status \[not working (including homemakers and retirees), working part-time, or working full-time\] and net monthly household income \[\<1500 €, 1500-\<3000 €, or ≥3000 €\]) as well as the Dermatology Life Quality Index (DLQI).

In the second part, participants' preferences for treatment of psoriasis with biologicals were explored using CA, generated and evaluated basically as described \[[@pone.0129120.ref018]\]. Seven key outcome attributes (probability of 50% improvement, probability of 90% improvement, time until response, sustainability of success, probability of mild adverse events (AE), probability of severe AE, and probability of ACR 20 response) and four process attributes (treatment location, frequency, duration, and delivery method) were selected ([Table 1](#pone.0129120.t001){ref-type="table"}). Literature research including randomized controlled trials, guidelines, reviews and meta-analyses was performed to identify four realistic levels for each attribute that reflected characteristics of TNF antagonists and ustekinumab as closely as possible (e.g., \[[@pone.0129120.ref004]--[@pone.0129120.ref010]; [@pone.0129120.ref023]--[@pone.0129120.ref026]\]). Attributes were assigned to two groups, each with six attributes, to prevent information overload. Treatment duration was included into both groups to enable same-scaled comparison across all attributes. The two attributes describing efficacy (probability of 50% and 90% improvement) were presented in different groups. The probability of 90% improvement was depicted as chance of almost complete clearance. Examples of discrete choice scenarios with attributes of group 1 and group 2 are provided in [Table 2](#pone.0129120.t002){ref-type="table"}. The CA exercises did not contain a cost attribute, because treatment costs for biologicals are usually covered by health insurance in Germany.

10.1371/journal.pone.0129120.t001

###### Outcome and process attributes and attribute levels used in the conjoint scenarios.

![](pone.0129120.t001){#pone.0129120.t001g}

  Outcome attribute                                                             Level
  ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  Probability of 50% improvement                                                90--95%
                                                                                85--90%
                                                                                80--85%
                                                                                70--80%
  Probability of 90% improvement                                                50--60%
                                                                                40--50%
                                                                                30--40%
                                                                                20--30%
  Time until response                                                           2 weeks
                                                                                4 weeks
                                                                                8 weeks
                                                                                12 weeks
  Sustainability of therapeutic success[^1^](#t001fn001){ref-type="table-fn"}   20%
                                                                                15%
                                                                                10%
                                                                                5%
  Probability of mild AE                                                        50--70%
                                                                                30--50%
                                                                                10--30%
                                                                                \<10%
  Probability of severe AE                                                      5--10%
                                                                                2--5%
                                                                                1--2%
                                                                                \<1%
  Probability of ACR 20 response                                                50--60%
                                                                                40--50%
                                                                                30--40%
                                                                                20--30%
  **Process attribute**                                                         **Level**
  Treatment location                                                            at home
                                                                                at a general practitioner's office
                                                                                at a dermatologist's office
                                                                                as an outpatient in a hospital
  Treatment frequency                                                           once to twice per week
                                                                                every two weeks
                                                                                every 4--8 weeks
                                                                                every 12 weeks
  Delivery method                                                               syringes into the subcutaneous fatty tissue administered by the patient
                                                                                syringes into the subcutaneous fatty tissue administered by medically trained persons
                                                                                injections into the subcutaneous fatty tissue with a pen administered by the patient
                                                                                infusions administered by a doctor
  Treatment duration[^2^](#t001fn002){ref-type="table-fn"}                      5 minutes
                                                                                15--30 minutes
                                                                                1 hour
                                                                                2--3 hours

^1^ Probability of loss of response within one year

^2^ per treatment session

AE: adverse events.

10.1371/journal.pone.0129120.t002

###### Examples of discrete choice scenarios.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Group 1**                                                                                                                                                                          
  **Out of the two therapeutic options, please choose the one that you prefer.**                                                                                                       
  ***Option 1***                                                                                                                                                                       ***Option 2***
  The probability of reduction of my psoriasis by half is 90--95%.                                                                                                                     The probability of reduction of my psoriasis by half is 80--85%.
  The time until response is ca. 8 weeks.                                                                                                                                              The time until response is ca. 2 weeks.
  The risk of mild adverse events (e.g., mild infections, injection-site reactions, headache, gastrointestinal symptoms, mild temporary change of laboratory parameters) is 35--50%.   The risk of mild adverse events (e.g., mild infections, injection-site reactions, headache, gastrointestinal symptoms, mild temporary change of laboratory parameters) is less than 10%.
  The probability of improvement of psoriatic arthritis is 40--50%.                                                                                                                    The probability of improvement of psoriatic arthritis is 20--30%.
  My treatment will be administered every 2 weeks.                                                                                                                                     My treatment will be administered every 12 weeks.
  Each treatment will take 1 hour.                                                                                                                                                     Each treatment will take 5 minutes.
  **Group 2**                                                                                                                                                                          
  **Out of the two therapeutic options, please choose the one that you prefer.**                                                                                                       
  ***Option 1***                                                                                                                                                                       ***Option 2***
  The probability of almost complete clearing of my psoriasis is 20--30%.                                                                                                              The probability of almost complete clearing of my psoriasis is 50--60%.
  The probability that the efficacy of the treatment will decrease within one year is ca. 5%.                                                                                          The probability that the efficacy of the treatment will decrease within one year is ca. 10%.
  The risk of severe adverse events (e.g., tuberculosis, other severe infections, severe intolerance reactions, autoimmune diseases) is less than 1%.                                  The risk of severe adverse events (e.g., tuberculosis, other severe infections, severe intolerance reactions, autoimmune diseases) is 2--5%.
  My treatments will take place at home.                                                                                                                                               My treatments will take place as an outpatient in a hospital.
  My treatments include injections into the subcutaneous fatty tissue with an easy-to-handle injection pen which I administer myself.                                                  My treatments include infusions administered by a doctor.
  Each treatment will take 5 minutes.                                                                                                                                                  Each treatment will take 2--3 hours.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Participants were confronted with hypothetical treatment scenarios, designed by utilizing CBC/HB feature of commercially available CA software ([http://www.sawtoothsoftware.com](http://www.sawtoothsoftware.com/)). This software created all possible combinations of attribute levels per group and randomly selected twelve pairs of scenarios of each group for each respondent by using a random-orthogonal method. In each experiment, respondents had to choose their preferred option with higher net utility. Three fixed experiments with one option being superior in every attribute were presented to each participant for control.

PASI was recorded by two investigators (C.K. and M.-L.S.). Part-worth utilities for each attribute level were computed using logit regression, with positive values indicating high utility and negative values representing disutility. The range between the highest and the lowest part-worth utility within one attribute was used to calculate the attribute's Relative Importance Score (RIS) as fraction of one attribute's range across the sum of all ranges. To compare results between attributes of group 1 and 2, attribute importance was translated into one list by matching the relative importance of treatment duration. Logarithmic transformations (Log~10~; for PASI, DLQI, probability of 50% improvement, time until response, probability of ACR 20 response, treatment frequency, duration, and delivery method) and square root transformations (for probability of 90% improvement, sustainability of success, probability of mild and severe AE, and treatment location) were applied to obtain normal distribution of the variables.

SPSS software was used for subgroup analyses. Associations of RIS with categorical variables were analysed by ANOVA (analysis of variance). Post hoc tests with Bonferroni correction were performed in cases of more than two subgroups. Pearson's Correlations (PC) were used for continuous factors. For sensitivity reasons, analyses were repeated using untransformed variables with non-parametric tests (Kruskal-Wallis Test for ANOVAs and Spearman\'s rho for correlations). Significance was assumed at p≤0.05.

Regression analysis {#sec005}
-------------------

Multivariate linear regression analysis was performed to estimate independent associations between participants' characteristics and RIS. Eleven models were created including age, gender, partnership, working status, DLQI, and PASI as independent variables and each attribute's RIS as dependent variable. As monthly income did not significantly impact RIS according to descriptive analyses, this variable was not taken into account for the models. Standardized regression coeffients (β) were assigned to each independent variable, indicating the amount of change in RIS when varying one of the variables while holding the others constant.

Results {#sec006}
=======

239 patients were asked to participate; 210 met study criteria and provided written informed consent. Out of these, 10 had to be excluded, 9 because of difficulties with the German language and one due to inability understand the CA exercises. 200 participants completed the survey (57.5% male, mean age: 50.8 years; for further characteristics see [Table 3](#pone.0129120.t003){ref-type="table"}). The vast majority (95.5%) came for a follow-up visit, and 99% currently received antipsoriatic treatment. 18.5% of the participants (n = 37) were treated exclusively with topical therapy, 58% (n = 116) with topical therapy in combination with another treatment modality, 10% (n = 20) with phototherapy, 37.5% (n = 75) with traditional systemic antipsoriatic medication and 43.5% (n = 87) with biologicals at the time of data collection. Therefore the mean PASI was relatively low (3.4, range: 0--26.7). The mean DLQI was 6.2 (range: 0--30), corresponding to moderate disease-related life quality impairment.

10.1371/journal.pone.0129120.t003

###### Characteristics of the study cohort.
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  Category                                                                      N (%)[^1^](#t003fn001){ref-type="table-fn"}
  ----------------------------------------------------------------------------- ---------------------------------------------
  **Gender**                                                                    
  Female                                                                        85 (42.5)
  Male                                                                          115 (57.5)
  **Age (years)**                                                               
  Mean (SD)                                                                     50.8 (14.1)
  Median (min-max; IQR)                                                         51 (18--84; 17.8)
  **Partnership**                                                               
  Living with a partner                                                         121 (60.5)
  Living without a partner                                                      79 (39.5)
  **Occupational status** [^2^](#t003fn002){ref-type="table-fn"}                
  Working full-time                                                             102 (51)
  Working part-time                                                             30 (15)
  Not working[^3^](#t003fn003){ref-type="table-fn"}                             62 (31)
  **Net monthly household income (€)** [^4^](#t003fn004){ref-type="table-fn"}   
  \<1500                                                                        40 (20)
  1500--3000                                                                    75 (37.5)
  ≥3000                                                                         39 (19.5)
  **PASI**                                                                      
  Mean (SD)                                                                     3.4 (4.1)
  Median (min-max; IQR)                                                         2 (0--26.7; 4.4)
  **DLQI**                                                                      
  Mean (SD)                                                                     6.2 (7.1)
  Median (min-max; IQR)                                                         4 (0--30; 9)
  **Disease duration**                                                          
  Mean (SD)                                                                     19.9 (13.1)
  Median (min-max; IQR)                                                         19.5 (1--60; 21)
  **Psoriatic arthritis**                                                       45 (22.5)

^1^ Mean (SD) and median (min-max; IQR) are indicated for age, PASI and DLQI. N (%) are displayed for all other variables.

^2^ Information on the working status was unavailable for 6 participants (3%).

^3^ The subgroup of non-working participants comprised 51 retirees and 11 younger individuals who were either homemakers or unemployed.

^4^ 46 participants (23%) did not want to disclose their net monthly household income.

DLQI: Dermatology Life Quality Index; IQR: interquartile range; max: maximum; min: minimum; N: number; PASI: Psoriasis Area and Severity Index; SD: standard deviation.

Patients' preferences averaged across the study sample {#sec007}
------------------------------------------------------

The attribute regarded as most important in the whole study collective was probability of severe AE (RIS = 17.3), followed by probability of 90% improvement (RIS = 14.0) and probability of mild AE (RIS = 10.5). Time until response (RIS = 4.5), sustainability of success (RIS = 5.2) and probability of ACR 20 response (RIS = 6.2) were rated less important. All process attributes reached RIS between 8.2 and 8.8 ([Fig 1](#pone.0129120.g001){ref-type="fig"}).

![Relative Importance Scores (RIS) averaged across the study cohort.\
The probability of severe AE was evaluated as most important (RIS = 17.3), followed by the probability of 90% improvement (RIS = 14.0). Time until response (RIS = 4.5) and sustainability of the therapeutic success (RIS = 5.2) were least relevant. Bars: Means with standard deviations.](pone.0129120.g001){#pone.0129120.g001}

Impact of sociodemographic and socioeconomic characteristics, PASI and DLQI on preferences {#sec008}
------------------------------------------------------------------------------------------

Subgroup analyses according to gender revealed that men were more concerned about the probability of 50% and 90% improvement than women (50% improvement: RIS = 9.5 vs. 6.9, p = 0.008; 90% improvement: RIS = 15.4 vs. 12.1, p = 0.002, [Fig 2A](#pone.0129120.g002){ref-type="fig"}). According to regression analyses these results were independent of age, partnership, working status, PASI and DLQI (50% improvement: β = -0.191, p = 0.011; 90% improvement: β = -0.197, p = 0.009, [Table 4](#pone.0129120.t004){ref-type="table"}). Furthermore, models adjusted for these factors showed that women attached greater value to treatment frequency than men (β = 0.161, p = 0.035, [Table 5](#pone.0129120.t005){ref-type="table"}).

![Impact of gender, age, partnership and working status on patients' preferences.\
(A) Men attached higher value to the probability of 50% and 90% improvement than women. (B) Probability of 50% and 90% improvement, time until response and treatment frequency became less important with increasing age whereas probability of severe AE and probability of ACR 20 response gained relevance. (C) Participants without a partner placed greater importance on the probability of 50% improvement while respondents with a partner valued the probability of ACR 20 response higher. (D) Compared to non-working participants, full-time working participants set higher priority to time until response, treatment location, and treatment frequency. The probability of 90% improvement was more important for full-time working than for part-time working participants. Part-time working participants considered the delivery method more important than non-working participants. Differences in RIS were tested for significance with ANOVA (A, C), 2-tailed t-test (B) or Bonferroni post-hoc tests (D). Bars: Means with standard deviations (A, C, D) or Pearson's Correlations (B). RIS: Relative Importance Scores. \* p≤0.05, \*\* p≤0.01.](pone.0129120.g002){#pone.0129120.g002}

10.1371/journal.pone.0129120.t004

###### Multivariate linear regression models for outcome attributes.
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  Outcome attributes                                                                                                                                                                          
  -------------------------------------------------------------- ------------ ---------- ------------ ---------- -------- ------ -------- ------ -------- ------ -------- ------ ------------ ----------
  **Female** [^1^](#t004fn002){ref-type="table-fn"}              **-0.191**   **.011**   **-0.197**   **.009**   0.094    .221   -0.018   .823   0.054    .490   0.011    .883   0.135        .074
  **Age**                                                        **-0.219**   **.017**   **-0.264**   **.004**   -0.146   .123   0.088    .360   0.113    .236   0.166    .082   0.108        .245
  **No partner** [^2^](#t004fn003){ref-type="table-fn"}          **0.146**    **.044**   0.005        .948       -0.063   .402   0.023    .762   -0.014   .848   0.027    .719   **-0.196**   **.008**
  **Part-time working** [^3^](#t004fn004){ref-type="table-fn"}   0.003        .967       -0.129       .094       -0.065   .413   0.028    .723   0.108    .177   0.082    .304   -0.144       .064
  **Not working** [^3^](#t004fn004){ref-type="table-fn"}         0.12         .189       0.169        .067       -0.11    .246   0.082    .398   -0.032   .740   0.031    .749   -0.001       .994
  **PASI**                                                       -0.023       .77        -0.032       .684       -0.036   .658   0.012    .882   0.107    .188   0.032    .694   -0.006       .935
  **DLQI**                                                       **-0.168**   **.031**   0.024        .755       0.06     .456   0.08     .326   0.046    .567   -0.083   .304   0.08         .312

The RIS was defined as dependent variable; gender, age, partnership, working status, DLQI and PASI were used as independent variables. β represents the standardized regression coefficient. For metric variables (age, DLQI, PASI) a positive β-value indicates that the attribute gains importance with increase of the characteristic whereas a negative β-value indicates loss of importance of the attribute with increase of the characteristic. For all other variables a positive β indicates a higher importance of the attribute compared to the reference group. Statistically significant findings are highlighted in bold.

^1^ The reference group for "female" was male.

^2^ The reference group for "no partner" contained all participants living in a partnership.

^3^ The reference group for "part-time working" and "not working" comprised all participants working full-time.

DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area and Severity Index; RIS: Relative Importance Score.

10.1371/journal.pone.0129120.t005

###### Multivariate linear regression models for process attributes.
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  Process attributes                                                                                                                      
  -------------------------------------------------------------- ------------ ---------- ------------ ---------- -------- ------ -------- ------
  **Female** [^1^](#t005fn002){ref-type="table-fn"}              0.01         .901       **0.161**    **.035**   0.02     .797   0.063    .409
  **Age**                                                        -0.023       .808       -0.086       .357       -0.029   .757   0.173    .066
  **No partner** [^2^](#t005fn003){ref-type="table-fn"}          -0.054       .473       -0.115       .123       -0.053   .482   -0.038   .613
  **Part-time working** [^3^](#t005fn004){ref-type="table-fn"}   0.015        .845       -0.051       .511       0.129    .106   0.065    .405
  **Not working** [^3^](#t005fn004){ref-type="table-fn"}         **-0.187**   **.051**   **-0.192**   **.042**   -0.093   .333   -0.029   .760
  **PASI**                                                       -0.08        .322       0.019        .811       -0.069   .393   0.107    .181
  **DLQI**                                                       -0.007       .933       -0.007       .931       0.044    .590   0.147    .066

For explanations and abbreviations, see [Table 4](#pone.0129120.t004){ref-type="table"}.

^1^ The reference group for "female" was male.

^2^ The reference group for "no partner" contained all participants living in a partnership.

^3^ The reference group for "part-time working" and "not working" comprised all participants working full-time.

DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area and Severity Index; RIS: Relative Importance Score.

Older participants judged the probability of 50% and 90% improvement less important than younger ones (50% improvement: PC = -0.161, p = 0.022; 90% improvement: PC = -0.155, p = 0.028, [Fig 2B](#pone.0129120.g002){ref-type="fig"}), findings substantiated in adjusted regression models (50% improvement: β = -0.219, p = 0.017; 90% improvement: β = -0.264, p = 0.004, [Table 4](#pone.0129120.t004){ref-type="table"}). However, older participants worried more about severe AE (PC = 0.175, p = 0.013; β = 0.166, p = 0.082). According to bivariate analyses, ACR 20 response appeared more relevant (PC = 0.150, p = 0.035) but time until response (PC = -0.195, p = 0.006) and treatment frequency (PC = -0.146, p = 0.039) less relevant with increasing age ([Fig 2B](#pone.0129120.g002){ref-type="fig"}).

Participants living without a partner were more interested in 50% improvement than those with a partner (RIS = 10.1 vs. 7.3, p = 0.015, [Fig 2C](#pone.0129120.g002){ref-type="fig"}; β = 0.146, p = 0.044, [Table 4](#pone.0129120.t004){ref-type="table"}). However, they were less concerned about ACR 20 response (RIS = 5.0 vs. 6.9; p = 0.004, β = -0.196, p = 0.008).

Monthly household income had no statistically significant impact on preferences, but preferences were influenced by working status ([Fig 2D](#pone.0129120.g002){ref-type="fig"}, [Table 5](#pone.0129120.t005){ref-type="table"}). Probability of 90% improvement was more important for participants working full-time compared to those working part-time (RIS = 14.8 vs. 10.7, p = 0.033). Furthermore, participants with a full-time job were more interested in time until response (RIS = 3.4 vs. 5.2, p = 0.042), treatment location (RIS = 7.2 vs. 9.4, p = 0.026; β = -0.187, p = 0.051) and treatment frequency (RIS = 7.0 vs. 9.7, p = 0.018; β = 0.192, p = 0.042) than non-working participants. Participants working part-time were more concerned about the delivery method than those without work (RIS = 7.2 vs. 10.0, p = 0.016).

Treatment duration became more important with rising PASI (PC = 0.160, p = 0.024, [Fig 3A](#pone.0129120.g003){ref-type="fig"}) and rising DLQI (PC = 0.175, p = 0.013, [Fig 3B](#pone.0129120.g003){ref-type="fig"}; β = 0.147, p = 0.066, [Table 5](#pone.0129120.t005){ref-type="table"}). Unexpectedly, the RIS for probability of 50% improvement was negatively correlated with DLQI (PC = -0.158, p = 0.026, [Fig 3B](#pone.0129120.g003){ref-type="fig"}), indicating that participants with higher disease-related quality of life impartment were less interested in reduction of their psoriasis by half. This finding was confirmed in multivariate regression models (β = -0.168, p = 0.031, [Table 4](#pone.0129120.t004){ref-type="table"}).

![Impact of PASI and DLQI on Relative Importance Scores (RIS).\
With increasing PASI (A) and increasing DLQI (B), participants set greater value on treatment duration. The higher the DLQI score, the less importance was attached to probability of 50% improvement. Differences in RIS were tested for significance with 2-tailed t-tests. Bars: Pearson's Correlations. \* p≤0.05.](pone.0129120.g003){#pone.0129120.g003}

Discussion {#sec009}
==========

In our study we applied a method closely resembling clinical decision-making for the identification of patients' preferences for biologicals. Attributes and attribute levels reflected characteristics of biologicals approved for psoriasis in Germany as accurately as possible in order to create choice scenarios close to reality. We show that participants attach the greatest importance to avoidance of severe AE, in line with CA from Seston et al., according to which psoriasis patients were willing to trade time until response for a reduced risk of severe AE, particularly skin cancer and liver damage \[[@pone.0129120.ref016]\].

We previously performed CA to assess patients' preferences for all treatment options currently available for psoriasis \[[@pone.0129120.ref018]\]. In these experiments patients prioritized process attributes over outcome. The attribute regarded as most important was treatment location, probably because participants were confronted with the option of a three-week hospitalization for treatment with dithranol, which they disliked \[[@pone.0129120.ref018]\]. Under the prerequisite of an outpatient setting and given the overall convenient treatment process associated with biologicals, participants care only moderately about the treatment process. Regarding the delivery method, our part-worth utilities indicated than an injection pen was most preferred, followed by subcutaneous syringes, a finding well in accordance with other studies (e.g., \[[@pone.0129120.ref027]\]).

The relevance attributed to AE can be largely influenced by the examples given, because patients tend to imagine these conditions and emphasize them during their decision-making, a phenomenon called the framing effect \[[@pone.0129120.ref028]\]. In our previous study comparing preferences for all treatment modalities, utilities for AE were assessed without giving specific examples, since none of them could have applied to all options at once, and RIS for AE-related attributes were low. Here we included examples of several important mild and severe AE of biologicals. As the amount of information had to be limited, it was impossible to mention each potential AE. In addition, our study does not allow conclusions on how the different kinds of AE can influence preferences. The perception of rare AE can vary immensely depending on how they are presented to the patients. When weighing AE against efficacy, it has to be taken into account that the mean PASI of our participants was relatively low. Thanks to their actually good disease control, participants might have focused more on AE than on clearing.

Regarding efficacy, we assessed utilities of 50% and 90% improvement instead of PASI 75 response rate, which is the most common primary endpoint of clinical trials. First, 50% and 90% improvement is easier to imagine for study participants than PASI 75 response. Second, 90% improvement rates of currently available biologicals, roughly reflecting PASI 90 responses, differ stronger than their PASI 75 response rates. Third, we wanted to examine whether 50% improvement is still a worthwhile treatment goal for patients. Not surprisingly, probability of 90% improvement was identified as the second most important attribute. Efficacy is a key predictor of satisfaction with antipsoriatic medications \[[@pone.0129120.ref012],[@pone.0129120.ref029]\]. High prioritization of 90% improvement may indicate that in the era of biologicals patients' expectations are rising towards (nearly) complete clearance. However, participants still valued 50% improvement.

When stratifying the RIS for gender, men put higher emphasis on treatment efficiency. This result is surprising, considering that women usually attach greater importance to appearance \[[@pone.0129120.ref030]\] and suffer more from their psoriasis than men, both mentally and physically \[[@pone.0129120.ref031]\].

Older study participants were willing to trade efficacy and rapidity of response for safety, corresponding to our previous observations \[[@pone.0129120.ref018]\]. Indeed, older patients have a higher risk of concomitant diseases and AE from medication \[[@pone.0129120.ref032],[@pone.0129120.ref033]\]. Therefore, they might be unwilling to accept additional risks of systemic antipsoriatic treatments.

Participants living without a partner valued 50% improvement higher, possibly due to expectations from society and potential partners \[[@pone.0129120.ref018]\]. However, they were less interested in ACR 20 response. The prevalence of psoriatic arthritis rises with increasing age and duration of psoriasis. Participants without a partner were in average younger than those with a partner (mean age: 46.9 vs. 53.3 years) but the difference in utilities of ACR 20 response was still statistically significant in multivariate models controlling for age.

Participants working full-time put emphasis on a treatment well compatible with work, i.e., on high probability of 90% improvement, rapid onset of action, low treatment frequency, and a convenient treatment location. Psoriasis can substantially impair work productivity, \[[@pone.0129120.ref034],[@pone.0129120.ref035]\] and working patients might feel pressure to reduce absenteeism. The subgroup of participants who were not working comprised homemakers, unemployed and retired participants. It is well conceivable that preferences of homemakers and retired persons differ from those of unemployed patients. Accordant analyses were impossible here due to the study design and the limited cohort size but will be interesting to perform in future larger-scale studies.

The study cohort was heterogeneous with regard to PASI and DLQI and the mean PASI was relatively low, but these parameters were indicative of disease control and not of global disease severity, since virtually all participants received treatment at the time of study participation. Participants with higher PASI and higher DLQI were particularly interested in a time-saving treatment.

A limitation of our study is that it only comprised patients with moderate-to-severe psoriasis treated at a German University Hospital. Clearly, our findings will have to be verified in larger cohorts and in a multi-centric setting. Moreover, it is likely that preferences can be influenced by further factors such as comorbidities and treatment experience. For example, patients with psoriatic arthritis are more interested in ACR 20 response than others (Schaarschmidt et al., manuscript in preparation). 46% of the participants had experience with biologicals, but all were candidates for these medications and may be confronted with treatment decisions involving biologicals.

A major limitation of conjoint analysis is that the discrete choice experiments are theoretical and actual patients may choose actual medications differently. Moreover, average preferences presented here do not allow direct conclusions for each individual. Clearly, treatment decisions for a particular patient are based on his or her individual preferences. However, when starting to discuss treatment options with an individual, it is extremely helpful for physicians to know what most patients are interested in and concerned about and how preferences may be systematically influenced by sociodemographic and disease-related characteristics. Based on this knowledge, physicians should work out the preferences, needs and concerns of each individual patient and integrate them into therapeutic decisions in order to optimize treatment satisfaction, adherence and outcome.
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